Vivek Jain - 01 Nov 2024 Form 4 Insider Report for ICU MEDICAL INC/DE (ICUI)

Role
Chairman and CEO, Director
Signature
By: Paula Darbyshire, Attorney-in-fact For: Vivek Jain
Issuer symbol
ICUI
Transactions as of
01 Nov 2024
Net transactions value
-$997,016
Form type
4
Filing time
04 Nov 2024, 19:32:27 UTC
Previous filing
01 Oct 2024
Next filing
02 Dec 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ICUI Common Stock Options Exercise $1,065,120 +12,000 +11% $88.76 116,593 01 Nov 2024 Direct F1
transaction ICUI Common Stock Sale $721,933 -4,228 -3.6% $170.75 112,365 01 Nov 2024 Direct F2, F3
transaction ICUI Common Stock Sale $712,905 -4,147 -3.7% $171.91 108,218 01 Nov 2024 Direct F2, F4
transaction ICUI Common Stock Sale $412,212 -2,386 -2.2% $172.76 105,832 01 Nov 2024 Direct F2, F5
transaction ICUI Common Stock Sale $215,087 -1,239 -1.2% $173.60 104,593 01 Nov 2024 Direct F2, F6
holding ICUI Common Stock 88,698 01 Nov 2024 by Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ICUI Non-Qualified Stock Option (right to buy) Options Exercise $0 -12,000 -47% $0.000000 13,373 01 Nov 2024 Common Stock 12,000 $88.76 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2024.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2024.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $170.28 to $171.23, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $171.25 to $172.23, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $172.275 to $173.175, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $173.44 to $173.91, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.